New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
04:55 EDTMRGE, MRGE, KND, KND, IMMU, IMMU, COO, COO, CVS, CVS, ARNA, ARNA, GMED, GMED, ISIS, ISIS, Q, Q, STML, STML, BDSI, BDSI, DEPO, DEPOWells Fargo to hold a conference
2014 Healthcare Conference to be held in Boston on June 17-18.
News For MRGE;BDSI;STML;Q;ISIS;GMED;ARNA;CVS;COO;IMMU;KND;DEPO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 25, 2015
16:37 EDTCVSSpecialists On Call names Hammad Shah as CEO
Subscribe for More Information
11:45 EDTCVSLeerink healthcare tech/pharma analysts hold analyst/industry conference call
Subscribe for More Information
07:16 EDTQPiper Jaffray and the Alliance for Regenerative Medicine co-host conference
3rd Annual Regenerative Medicine Investor Day is being held in New York on March 25 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link
March 24, 2015
07:21 EDTCOOCooper Companies outlook has improved, says Wells Fargo
After speaking with sources at the Global Contact Lens Forum at Vision Expo, Wells Fargo is more confident in Cooper's accelerating growth outlook in fiscal 2015 and beyond, driven by what the firm sees as the company's ability to gain share in the fast growing multifocal and daily lens market segments. The firm raised its price target range on the shares to $202-$203 from $184-$185 and keeps an Outperform rating on the stock.
March 23, 2015
08:07 EDTKNDBofA/Merrill healthcare high yield analyst has analyst/industry conference call
Healthcare High Yield Analyst Bland provides an update on the current state of the bond markets and the ability of healthcare providers to utilize debt financing on an Analyst/Industry conference call to be held on March 24 at 10 am.
07:04 EDTISISIsis Pharmaceuticals says ISIS-ANGPTL3Rx 'well tolerated' in Phase 1 study
Isis Pharmaceuticals announced positive results from a Phase 1 study with ISIS-ANGPTL3Rx. In this study, healthy volunteers treated with ISIS-ANGPTL3Rx achieved dose-dependent, statistically significant reductions in angiopoietin-like 3 of up to 93% with a mean reduction of up to 84% from baseline. In addition, statistically significant reductions from baseline in lipid parameters were observed, including up to 63% with a mean reduction of up to 49% in triglycerides and up to 46% with a mean reduction of up to 28% in total cholesterol. ANGPTL3 is a protein that acts as a key regulator of these blood lipids. These data were presented at the 83rd European Atherosclerosis Society in Glasgow, United Kingdom. The Phase 1 study of ISIS-ANGPTL3Rx was a blinded, placebo-controlled, dose-escalation study in healthy volunteers. The study was designed to assess the safety, tolerability and pharmacokinetics of ISIS-ANGPTL3Rx. ISIS-ANGPTL3Rx was evaluated in single and multiple doses ranging from 50 mg per week up to 400 mg per week for the single dose and 100 mg per week up to 400 mg per week for the multiple dose. In this study, ISIS-ANGPTL3Rx was generally well tolerated.
March 20, 2015
15:16 EDTBDSIBioDelivery Sciences April volatility elevated
Subscribe for More Information
11:45 EDTISISIsis Pharmaceuticals management to meet with Needham
Subscribe for More Information
10:00 EDTCOOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:32 EDTCOOCooper Companies management to meet with JPMorgan
Subscribe for More Information
March 19, 2015
16:08 EDTCOOCooper Companies initiated with an Overweight at Piper Jaffray
Subscribe for More Information
10:02 EDTDEPOOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:22 EDTDEPODepomed downgraded to Neutral at Janney Capital
Subscribe for More Information
08:16 EDTDEPODepomed downgraded to Neutral from Buy at Janney Capital
Subscribe for More Information
06:15 EDTMRGEMerge Healthcare coverage transferred with an Outperform at RW Baird
Target $5.
March 17, 2015
10:00 EDTISISOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Aimco (AIV) initiated with an Outperform at RW Baird... Alnylam (ALNY) initiated with a Buy at Janney Capital... American Campus (ACC) initiated with a Neutral at RW Baird... AvalonBay (AVB) initiated with a Neutral at RW Baird... BE Aerospace (BEAV) initiated with a Buy at CRT Capital... BlackRock (BLK) initiated with a Buy at Argus... Camden Property (CPT) initiated with an Outperform at RW Baird... CarMax (KMX) initiated with a Buy at Evercore ISI... Central Pacific (CPF) initiated with a Neutral at Macquarie... Cognex (CGNX) initiated with a Buy at Northcoast... Education Realty (EDR) initiated with a Neutral at RW Baird... EnerSys (ENS) initiated with an Overweight at Stephens... Equity Lifestyle (ELS) initiated with an Outperform at RW Baird... Equity Residential (EQR) initiated with a Neutral at RW Baird... Essex Property Trust (ESS) initiated with a Neutral at RW Baird... Facebook (FB) initiated with a Buy at Brean Capital... Intercept (ICPT) initiated with a Hold at MLV & Co.... Isis Pharmaceuticals (ISIS) initiated with a Neutral at Janney Capital... LinkedIn (LNKD) initiated with a Sell at Brean Capital... Mid-America Apartment (MAA) initiated with an Outperform at RW Baird... NetSuite (N) initiated with a Hold at Brean Capital... Paycom (PAYC) initiated with a Buy at Brean Capital... Platform Specialty Products (PAH) initiated with a Buy at UBS... Post Properties (PPS) initiated with a Neutral at RW Baird... Salesforce.com (CRM) initiated with a Hold at Brean Capital... ServiceNow (NOW) initiated with a Buy at Brean Capital... Snap-On (SNA) initiated with a Buy at Northcoast... Sun Communities (SUI) initiated with a Neutral at RW Baird... Twitter (TWTR) initiated with a Buy at Brean Capital... UDR, Inc. (UDR) initiated with an Outperform at RW Baird... Workday (WDAY) initiated with a Hold at Brean Capital... Xplore Technologies (XPLR) initiated with a Buy at Roth Capital... Yahoo (YHOO) initiated with a Hold at Argus.
09:25 EDTBDSIOn The Fly: Pre-market Movers
Subscribe for More Information
08:35 EDTDEPODepomed announces expiration of waiting period to acquire rights of NUCYNTA
Depomed announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired with respect to Depomed's pending acquisition of U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals. The termination of the waiting period under the HSR Act satisfies one of the conditions to the closing of the pending acquisition, which remains subject to completion of Depomed's previously announced financing and other customary closing conditions.
08:20 EDTISISIsis Pharmaceuticals initiated with a Neutral at Janney Capital
Subscribe for More Information
06:31 EDTCVSStudies find Gilead's hepatitis C drugs cost effective, Reuters says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use